**Sun Pharma Settles Patent Dispute with Incyte, Launches Leqselvi in the US**
**Meta Description:** Sun Pharma resolves patent issues with Incyte, launching Leqselvi for alopecia areata in the US, marking a significant milestone in hair-loss treatment.
**URL Slug:** sun-pharma-leqselvi-launch-us
**Headline:** Sun Pharma Resolves Patent Dispute with Incyte and Launches Leqselvi for Alopecia Areata in the US
Sun Pharma has announced a significant development in its ongoing patent dispute with Incyte Corporation, a US-based biopharmaceutical company. The resolution of this legal battle has cleared the path for Sun Pharma to launch its hair-loss treatment, Leqselvi (oral deuruxolitinib), in the United States. This announcement comes after a lengthy legal struggle that began last year.
Leqselvi is specifically indicated for the treatment of adults suffering from severe alopecia areata, a condition characterized by hair loss. Following the settlement, both companies will seek to dismiss the pending litigation in the United States District Court for the District of New Jersey. As part of the agreement, Sun Pharma and Incyte will mutually release each other from all claims related to the lawsuit. Incyte has also granted Sun Pharma a limited, non-exclusive license to certain US patents, including patent no. 9,662,335, which pertains to oral deuruxolitinib for specific non-hematology-oncology indications, including alopecia areata.
In exchange for this licensing agreement, Sun Pharma will provide Incyte with an upfront payment along with ongoing royalty payments until the patents expire. However, the specific terms of the settlement have not been disclosed.
Earlier this year, in April 2025, Sun Pharma received a favorable ruling from the US Court of Appeals for the Federal Circuit, which lifted a preliminary injunction that had previously restricted the launch of Leqselvi. The US Food and Drug Administration granted approval for Leqselvi in July 2024, but shortly thereafter, Incyte filed a patent infringement lawsuit against Sun Pharma, claiming that Leqselvi violated its existing patents, which delayed the product’s market entry. In November 2024, the US District Court of New Jersey issued a preliminary injunction that halted the launch of Leqselvi until the lawsuit was resolved.
With the settlement now in place, Sun Pharma has officially launched Leqselvi in the US, offering the drug in 8mg tablet form. Richard Ascroft, CEO of Sun Pharma North America, emphasized the company’s commitment to providing new therapeutic options for patients, stating that the addition of Leqselvi to their dermatology portfolio represents a significant milestone for the business and a vital advancement for the alopecia areata community.
Clinical trials for Leqselvi have shown promising results, with one-third of participants regaining nearly all of their hair by week 24, and some patients achieving over 80% scalp coverage as early as eight weeks into treatment. According to brokerage Elara Capital, Leqselvi is projected to become a $200 million opportunity for Sun Pharma within three to four years post-launch.
In conclusion, the resolution of the patent dispute with Incyte not only allows Sun Pharma to introduce Leqselvi to the US market but also highlights the company’s dedication to addressing the unmet needs of patients suffering from hair loss.
**FAQ:**
**What is Leqselvi used for?**
Leqselvi is an oral medication indicated for the treatment of adults with severe alopecia areata, a condition that causes significant hair loss.